Table 2:

Poliovirus type 2 response after vaccination with different study vaccines and schedules in modified intention-to-treat population

	4 weeks after two mOPV2 doses					4 weeks after two mOPV2 doses with or without IPV			4 weeks after one mOPV2 dose with or without IPV
	1 week group	2 week group	4 week group	1 week vs 4 week group (difference [90% CI] or p value)	2 week vs 4 week group (difference [90% CI] or p value)	4 week plus IPV group	4 week group	p value†	4 week plus IPV group	4 week group	p value†
Immune response	161/173 (93⋅1%; 88⋅3–96⋅0)	169/177 (95 5%; 91⋅3-97⋅7)	176/181 (97⋅2%; 93⋅7-98⋅8)	−4⋅2% (−7⋅9 to −0⋅4)*	−1⋅8% (−5⋅0 to 1⋅5)*	176/182 (96⋅7%; 93⋅0-98⋅5)	176/181 (97⋅2%; 93⋅7-98⋅8)	1⋅0	154/169 (91⋅1%; 85⋅9-94⋅6)	157/172 (91⋅3%; 86⋅1-94⋅6)	1⋅0
Antibody titres	1448 (1152⋅1448)	1448 (910⋅1448)	1448 (1152⋅1448)	p=0⋅243†	p=0⋅059†	1448 (1152⋅1448)	1448 (1152⋅1448)	0⋅758	1448 (724⋅1448)	1152 (724⋅1448)	0⋅691

Outcomes for poliovirus type 2 response include the proportion of infants with immune response expressed as n/N (%; 95% CI), and reciprocal antibody titres expressed as median (IQR). mOPV2=monovalent oral poliovirus vaccine type 2. IPV=inactivated poliovirus vaccine.

^*Non-inferiority test results are presented using the difference (experimental-standard) in the proportion of infants with immune response with 90% CIs.

^†Inequality hypothesis tests were done with Fisher's exact test for proportions and with Kruskal-Wallis test for antibody titre distributions.